Biotech

Merck Stays Confident On M&A Despite Market Uncertainty: Analyst

FDA Puts VYNE Therapeutics Early-Stage Psoriasis Study On Hold

AbbVie Raises Profit Outlook But Flags Tariff Risks In Pharma Sector

FDA Puts VYNE Therapeutics Early-Stage Psoriasis Study On Hold

AbbVie Raises Profit Outlook But Flags Tariff Risks In Pharma Sector

What's Going On With Summit Therapeutics Stock On Friday?

Novo Nordisk Wins Legal Battle To Curb Unsafe Knockoff Versions Of Ozempic, Wegovy

What's Going On With Summit Therapeutics Stock On Friday?

Novo Nordisk Wins Legal Battle To Curb Unsafe Knockoff Versions Of Ozempic, Wegovy

Gilead Sciences Stock Slips After Mixed Q1 Results, Lowered FY25 EPS Guidance

Guardant Health, Pfizer Collaborate To Develop New Cancer Therapies Using Liquid Biopsy Platform

Biotech Recent News

NovoCure Warns Of Potential $11 Million Tariff Hit If US Trade Pause Expires In 2025

NovoCure posted a smaller-than-expected Q1 loss with 12% revenue growth, while monitoring tariff shifts that could impact 2025 costs.

Bristol Myers Delivers Upbeat 2025 Forecast Despite China Tariffs Impact

Bristol Myers reported Q1 revenue of $11.2 billion, raised 2025 guidance, and saw strong Growth Portfolio sales offset Legacy product declines.

Merck's Q1 Earnings Beat Wall Street, Adjusts 2025 Profit Outlook As Tariffs May Result In Incremental Cost Of $200 Million

Merck posted Q1 adjusted EPS of $2.22 and revenue of $15.53 billion, beating estimates while revising full-year guidance amid tariff-related cost pressure.

Nano-Cap BriaCell Confirms Full Resolution Of Lung Metastasis In Breast Cancer Trial, Stock Shoots Higher

BriaCell confirms complete resolution of lung metastasis at 4 months in Phase 1/2a trial using Bria-OTS immunotherapy in advanced breast cancer.

French Drugmaker Sanofi Clocks 20% Q1 Profit Growth, Forecasts Strong Rebound In Annual Profit

Sanofi Q1 2025 revenue rose 10.8% to $10.42 billion, driven by Dupixent and new launches, as earnings climbed 20.1% and 2025 guidance was reaffirmed.

Elon Musk's Neuralink Eyes $8.5 Billion Pre-Money Valuation In Latest Funding Round: Report

Elon Musk's Neuralink plans to raise $500M, eyeing an $8.5B valuation amid talks with investors for latest funding round.

Viking Therapeutics Stock Dips After Q1 EPS Miss: Details

Viking Therapeutics releases its first-quarter results after Wednesday's closing bell. Here's a look at the details from the report.

Ensysce Biosciences Stock Doubles In One Trading Session - Here's Why

Ensysce Biosciences rises after patent notice for PF9001, a methadone prodrug aimed at safer opioid use with overdose protection technology.

Novavax's COVID-19 Vaccine Nears FDA Full Approval, Stock Jumps

Novavax's COVID-19 vaccine showed fewer side effects than Pfizer's in a Utah study as FDA seeks more data before full approval decision.

Rezolute 'Thrilled' With Positive Review Of Genetic Disorder Trial, Expects Topline Results In December

Rezolute advances HI drug trial after DMC review and secures $90 million in funding through stock offering to support development.

Why Is Summit Therapeutics Stock Soaring On Wednesday?

Summit and Akeso report Phase 3 success as ivonescimab shows PFS gains in NSCLC trial, with new studies and collaborations underway.

Merck Stock Slumps Ahead Of Q1 Earnings: Can Bulls Find Relief In Buying Pressure?

Merck & Co reports Q1 earnings on Thursday with EPS of $2.14 and revenue of $15.33B expected. Despite a 38.04% drop in stock over past year, analysts see ~30% upside potential.

Bristol Myers' Cobenfy Falls Short On Primary Endpoint In Phase 3 Schizophrenia Trial, Stock Slides

Bristol Myers' Cobenfy missed its primary endpoint in the Phase 3 ARISE trial but showed symptom improvement in certain subgroups.